Therapeutic strategies for multi-resistant Escherichia coli in urinary tract infections-a cause for concern
Abstract
Antimicrobial resistance (AMR) is a serious and growing public health concern driven by multiple factors. Urinary tract infection (UTI) is one of the infections commonly associated with AMR, and more than 80% of UTIs are caused by Escherichia coli. MDR E. coli is a significant problem that requires urgent intervention, particularly in complicated UTIs (cUTIs) with underlying comorbidities. Although prevalence rates of MDR E. coli vary globally, it remains a critical clinical and economic challenge on every continent. The majority of MDR E. coli strains produce ESBLs, followed by AmpC enzymes, making them generally resistant to penicillins, cephalosporins and aztreonam. While there are some therapeutic options for uncomplicated UTIs (uUTIs), choices are limited for cUTIs, with carbapenems being the mainstay of treatment. However, carbapenem resistance is on the rise, severely impeding clinical regimens. With very few options available, combinations of antimicrobial agents for synergistic activity are increasingly relied upon for carbapenem-resistant E. coli. This situation has compelled the search for novel antimicrobial agents, which are slowly entering the market, although not as quickly as AMR is spreading worldwide. Current focus is shifting towards alternative antimicrobial therapies that exhibit broad-spectrum bactericidal activity and immunomodulatory effects, considered for both preventive and therapeutic strategies. A multi-disciplinary approach combining novel…
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.